LOTIS-7 trial enrollment on track with efficacy and safety data on eligible patients expected by year-end 2024 and mature data on all patients expected in first half of 2025 Full enrollment in LOTIS-5 ...
Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Third Quarter 2024 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 7, 2024.
SAN FRANCISCO and SUZHOU, China, Dec. 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Fourth Quarter Fiscal Year 2024 Earnings Conference Call. At this time, all lines are in listen-only mode. Following the ...
ADC Therapeutics SA beats earnings expectations. Reported EPS is $-0.29, expectations were $-0.35. Operator: Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Fourth Quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results